|
JANUARY AND MARCH 2012 FINANCING (Details Textual) (USD $)
|
12 Months Ended | 67 Months Ended | |
|---|---|---|---|
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2012
|
|
| Debt Conversion, Converted Instrument, Shares Issued (in shares) | 199,250 | ||
| Entity's Volume Weighted Average Price | $ 34.60 | ||
| Warrants Exercise Terms and Expiration Description | In the event that the Companys average daily volume weighted average price was at or above $15.00 during the Measuring Period, the Class B Warrants were to expire unexercised. The Announcement Date was the earlier of (1) the date on which the Company announces via press release the results of the pharmacokinetic study of its TNX-102 drug formulation; or (2) June 1, 2012. On April 5, 2012 the Company issued a press release announcing the results of the pharmacokinetic study of its TNX-102 drug formulation, which is defined as an Announcement Date for the purpose of the Class B Warrants. Based on the Companys average daily volume weighted average price, which was $34.60 per share, during the Measuring Period, the Class B Warrants expired unexercised. | ||
| Change in fair value of warrant liability | $ 1,177,026 | $ 0 | $ 1,177,026 |
| Warrants Issued During Period To Purchase Common Stock | 1,538 | ||
| Stock Units Issued Upon Conversion Of Convertible Debt Purchase Price | 25,000 | ||
| Warrants reclassified to equity upon expiry of reset provisions | 3,938,946 | 0 | 3,938,946 |
| Warrants Exercise Price (in dollars per share) | $ 20.00 | ||
|
Common Stock [Member]
|
|||
| Number Of Shares Included In One Stock Unit (in shares) | 1,250 | ||
|
Warrant [Member]
|
|||
| Valuation Assumptions Issuance Date 1 | Jan. 20, 2012 | ||
| Valuation Assumptions Issuance Date 2 | Mar. 01, 2012 | ||
| Valuation Assumptions Expiration Date | Jun. 06, 2012 | ||
|
Additional Paid-In Capital [Member]
|
|||
| Warrants reclassified to equity upon expiry of reset provisions | 3,938,946 | ||
|
Placement Agents [Member]
|
|||
| Financing Arrangements Expense | 706,511 | ||
|
Placement Agents [Member] | Other Financing Cost [Member]
|
|||
| Financing Arrangements Expense | 270,798 | ||
|
Placement Agents [Member] | Additional Paid-In Capital [Member]
|
|||
| Financing Arrangements Expense | 435,713 | ||
|
Minimum [Member]
|
|||
| Percentage Of Investor Fee Payable Under Registration Rights Agreement | 1.00% | ||
|
Maximum [Member]
|
|||
| Percentage Of Investor Fee Payable Under Registration Rights Agreement | 10.00% | ||
|
Class A Warrant [Member]
|
|||
| Debt Conversion, Converted Instrument, Shares Issued (in shares) | 1,250 | ||
|
Class B Warrant [Member]
|
|||
| Debt Conversion, Converted Instrument, Shares Issued (in shares) | 1,250 | ||
| Entity Minimum Volume Weighted Average Price Effect On Exercise Warrants | $ 15.00 | ||
|
January 2012 Financing [Member]
|
|||
| Stock Units Issued During Period | 172.118 | ||
| Proceeds From Issuance Of Stock Units | 2,377,950 | ||
| Proceeds From Conversion Of Convertible Debentures | 1,925,000 | ||
| Warrants Issued During Period To Purchase Common Stock | 215,148 | ||
|
January 2012 Financing [Member] | Placement Agents [Member]
|
|||
| Warrants Issued During Period To Purchase Common Stock | 11,765 | ||
|
March 2012 Financing [Member]
|
|||
| Stock Units Issued During Period | 92.5926 | ||
| Proceeds From Issuance Of Stock Units | 2,314,815 | ||
| Warrants Issued During Period To Purchase Common Stock | 115,741 | ||
|
March 2012 Financing [Member] | Placement Agents [Member]
|
|||
| Warrants Issued During Period To Purchase Common Stock | 11,574 | ||
|
Financing Arrangements [Member]
|
|||
| Warrants Exercise Period | 7 years | ||
| Percentage Of Shares Issuable Upon Exercise Of Warrants | 10.00% | ||
| Warrants Exercise Price (in dollars per share) | $ 25.00 | ||
|
Financing Arrangements [Member] | Placement Agents [Member]
|
|||
| Payment For Commission | 466,777 | ||
| Percentage Of Commission Paid | 8.00% | ||
| Percentage Of Non Accountable Expenses | 2.00% | ||
| Warrants Issued During Period To Purchase Common Stock | 23,339 | ||
|
Financing Arrangements [Member] | Class A Warrant [Member]
|
|||
| Warrants Not Settleable In Cash Fair Value Disclosure | 2,549,684 | 2,549,684 | |
| Warrants Exercise Price (in dollars per share) | $ 25.00 | ||
|
Financing Arrangements [Member] | Agent Warrants [Member]
|
|||
| Warrants Not Settleable In Cash Fair Value Disclosure | $ 212,235 | $ 212,235 | |